References
- Brown JM, Wilson WR. (2004). Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4:437–447.
- Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–1095.
- Duan JX, Jiao H, Kaizerman J, Stanton T, Evans JW, Lan L, Lorente G, Banica M, Jung D, Wang J, Ma H, Li X, Yang Z, Hoffman RM, Ammons WS, Hart CP, Matteucci M. (2008). Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J Med Chem 51:2412–2420.
- Gibaldi M and Perrier D. (1982). Pharmacokinetics. New York, NY: Marcel Dekker.
- Hart CP, Ammons S, Duan JX, Jung D, Wang J, Jiao H, Meng F, Lan L, Evans JW and Matteucci M (2007). Discovery of TH-302: An achiral hypoxia-activated cytotoxic prodrug. J Clin Oncol 25: 3515.
- Kaanders JH, Wijffels KI, Marres HA, Ljungkvist AS, Pop LA, van den Hoogen FJ, de Wilde PC, Bussink J, Raleigh JA, van der Kogel AJ. (2002). Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 62:7066–7074.